Document Detail


Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer.
MedLine Citation:
PMID:  6275989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A phase I-II study of isotopic immunoglobulin therapy was performed in 18 patients with primary liver cancer; 14 were evaluable for toxicity. The patients received a dose of 37-157 millicuries of 131I-labeled antibody. The dose-limiting factor appears to be hematologic toxicity, especially thrombocytopenia. An objective antitumor effect was seen in six of nine patients who were evaluable for response. Present results suggest that further clinical studies with isotopic immunoglobulin are indicated.
Authors:
D S Ettinger; S E Order; M D Wharam; M K Parker; J L Klein; P K Leichner
Related Documents :
10426669 - Phase ii trial of 9-aminocamptothecin (nsc 603071) administered as a 120-hr continuous ...
8110489 - 21-day schedule oral etoposide in children--a feasibility study.
21785869 - Tumor budding and dedifferentiation in gallbladder carcinoma: potential for the prognos...
17058289 - Phase ii study of daily oral perifosine in patients with advanced soft tissue sarcoma.
2216299 - Comparative phase ii study of idarubicin versus doxorubicin in advanced breast cancer.
7524579 - Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic adminis...
3310349 - Secondary acute non lymphoid leukemia in patients treated for non hodgkin's lymphoma: n...
3821809 - Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherap...
25428339 - Application of response evaluation criteria of traditional chinese medicine for solid t...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  66     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1982 Feb 
Date Detail:
Created Date:  1982-04-20     Completed Date:  1982-04-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  289-97     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoma, Bile Duct / radiotherapy
Adolescent
Adult
Aged
Carcinoma, Hepatocellular / radiotherapy
Evaluation Studies as Topic
Female
Humans
Immunoglobulin G / administration & dosage
Immunoglobulins / administration & dosage*
Iodine Radioisotopes / therapeutic use
Leukopenia / etiology
Liver / radiation effects,  radionuclide imaging
Liver Neoplasms / radiotherapy*
Male
Middle Aged
Patients' Rooms
Radiation Dosage
Radioisotope Teletherapy / methods
Thrombocytopenia / etiology
Grant Support
ID/Acronym/Agency:
CA-06973/CA/NCI NIH HHS; CA-21661/CA/NCI NIH HHS; CA-29536/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Immunoglobulin G; 0/Immunoglobulins; 0/Iodine Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase II study of procarbazine in small cell carcinoma of the lung.
Next Document:  Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its f...